Business Context and Reporting Period
This Form 8-K filing by Becton, Dickinson and Company (BD) reports events occurring on February 8 and February 9, 2021. The company, incorporated in New Jersey, is a global medical technology firm. The report details two significant debt refinancing transactions: a U.S. dollar-denominated offering and a Euro-denominated offering.
Key Financial Metrics and Transactions
The filing focuses on capital structure adjustments rather than operational performance metrics like revenue or profit. Key transaction details include:
- U.S. Offering: BD entered an agreement to sell $1.0 billion aggregate principal amount of 1.957% Notes due 2031.
- Euro Offering: BD's subsidiary, Becton Dickinson Euro Finance S.à r.l., entered an agreement to sell €600 million aggregate principal amount of 1.213% Notes due 2036, fully guaranteed by BD.
- Use of Proceeds: Net proceeds from both offerings, combined with cash on hand, are intended to repay maturing debt (specifically $1.0 billion of 3.125% Notes due 2021 and €600 million of 0.174% Euro Notes due 2021) and cover associated fees and expenses.
- Closing Dates: The U.S. Offering is expected to close on or about February 11, 2021, and the Euro Offering on or about February 12, 2021.
Material Changes Versus Prior Period
This filing does not provide comparative financial data (e.g., revenue or earnings) against prior periods. The material change reported is the extension of the company's debt maturity profile. BD is replacing short-term debt maturing in 2021 with long-term debt maturing in 2031 and 2036, thereby altering its interest rate exposure and liquidity timeline.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on operational outlook. The primary risks and contingencies noted are:
- Closing Conditions: Both offerings are subject to customary closing conditions.
- Underwriter Holdings: Certain underwriters or their affiliates may hold portions of the maturing notes being repaid, meaning they may receive a portion of the new proceeds.
Important Facts for Investor Verification
- Verify the final closing of the $1.0 billion U.S. Notes and €600 million Euro Notes on the expected dates (Feb 11 and Feb 12, 2021).
- Confirm the successful repayment of the $1.0 billion 3.125% Notes due 2021 and the €600 million 0.174% Euro Notes due 2021.
- Review the full text of the Underwriting Agreements (Exhibits 1.1 and 1.2) for specific covenants and terms not detailed in this summary.
- Monitor the impact of the new interest rates (1.957% and 1.213%) on future interest expense compared to the maturing debt.